New Drug's brain activity measured in tiny early trial

NCT ID NCT07655518

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tests a new drug called BMS-986521 in 12 healthy adults. Researchers use PET scans to see how much of the drug reaches and attaches to M4 receptors in the brain. The goal is to learn about the drug's action, not to treat any illness. This is a first step before testing in patients with brain disorders.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

BMS-986521

What this could lead to

If successful, this study could help researchers understand how BMS-986521 interacts with brain receptors, potentially guiding future treatments for conditions like Alzheimer's or schizophrenia.

What could go wrong

This is a very early Phase 1 study with only 12 healthy volunteers. It is designed to measure brain activity, not to treat any disease. The drug may not work as expected or could cause side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Local Institution - 0001

    Leuven, 3000, Belgium

    Contact